This is a competitive renewal application on behalf of Case Western Reserve University's (CWRU) Program and its two primary teaching hospitals, MetroHealth Medical Center (MHMC) and University Hospitals of Cleveland Ireland Cancer Center (UH). The two institutions form ONE CONSORTIUM participation in ECOG activities. The CWRU program has been continuously funded for 34 years. This request describes all the integrated activities of our institution in ECOG and allows the continuation of the follow ing objectives and specific aims. 1) Permit the continuation of our participation in ECOG activities, with increased accrual to all disease oriented protocols including participation in surgical and radiation therapy oriented studies. The six-year main accrual total is 680. 2) Continue to provide follow up. The present follow up load consists of 563 patients. 3) Continue to maintain and develop additional scientific leadership in different disease committees. Dr. Hillard Lazarus has chaired the Bone Marrow Transplantation Committee, since the inception in ECOG. In the past six years, our researchers have authored 40 publications and 21 investigators/research staff are members of several ECOG committees/subcommittees. 4) Expand our participation in surgically oriented studies that require blood and tumor acquisition and perioperative adjuvant therapy. The PI is a surgical oncologist. 5) Develop Phase II and III studies that result from our Cancer Center Phase I Trials. 6) Extend Group activities of Phase I and II human studies. 7) Develop Phase I studies, as single institution or multi-institutional, and advance them to randomized clinical trials. 8) Participate in ancillary studies, chemo prevention, cancer control, and quality of Iife protocols. 9) Continue to monitor open and terminated adjuvant studies, chaired by CWRU investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA014548-38S1
Application #
8651971
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2014-02-28
Budget Start
2013-05-01
Budget End
2014-02-28
Support Year
38
Fiscal Year
2013
Total Cost
$334,918
Indirect Cost
$125,529
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Litzow, Mark R; Othus, Megan; Cripe, Larry D et al. (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148:217-25
Fernandez, Hugo F; Sun, Zhuoxin; Yao, Xiaopan et al. (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-59
Horn, Leora; Bernardo, Patricia; Sandler, Alan et al. (2009) A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol 4:527-33
Horn, Leora; Dahlberg, Suzanne E; Sandler, Alan B et al. (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-11
Dreicer, Robert; Li, Hailun; Cooney, Matthew M et al. (2008) Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer 112:2671-5
Gilbert, Jill; Li, Yi; Pinto, Harlan A et al. (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28:197-204
Cripe, Larry D; Rader, Kevin; Tallman, Martin S et al. (2006) Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. Leuk Res 30:823-7
Sandler, Alan; Gray, Robert; Perry, Michael C et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-50
Barlogie, Bart; Kyle, Robert A; Anderson, Kenneth C et al. (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929-36
Lazarus, Hillard M; Richards, Susan M; Chopra, Raj et al. (2006) Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 108:465-72

Showing the most recent 10 out of 42 publications